Carisma Therapeutics, Inc.

NasdaqGM:CARM Stok Raporu

Piyasa değeri: US$35.5m

Carisma Therapeutics Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Steve Kelly

İcra Kurulu Başkanı

US$3.5m

Toplam tazminat

CEO maaş yüzdesi13.2%
CEO görev süresi1.7yrs
CEO sahipliğin/a
Yönetim ortalama görev süresi1.5yrs
Yönetim Kurulu ortalama görev süresi1.7yrs

Son yönetim güncellemeleri

Recent updates

Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

Sep 02
Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

May 12
US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

Apr 19
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Mar 26
We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

Jan 21
Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Dec 07
The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

Nov 12
Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

Oct 05
Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

Jun 15
We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

CEO Tazminat Analizi

Steve Kelly'un ücretlendirmesi Carisma Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$64m

Jun 30 2024n/an/a

-US$73m

Mar 31 2024n/an/a

-US$81m

Dec 31 2023US$4mUS$461k

-US$87m

Sep 30 2023n/an/a

-US$83m

Jun 30 2023n/an/a

-US$80m

Mar 31 2023n/an/a

-US$75m

Dec 31 2022US$666kUS$440k

-US$61m

Sep 30 2022n/an/a

-US$57m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$43m

Dec 31 2021US$1mUS$416k

-US$41m

Tazminat ve Piyasa: Steve 'nin toplam tazminatı ($USD 3.50M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 646.00K ).

Tazminat ve Kazançlar: Steve şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Steve Kelly (59 yo)

1.7yrs

Görev süresi

US$3,504,425

Tazminat

Mr. Steven Kelly, also known as Steve, is President, Chief Executive Officer and Director of Carisma Therapeutics, Inc. He served as President, Chief Executive Officer and Director of CARISMA Therapeutics...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Steven Kelly
President1.7yrsUS$3.50mVeri yok
Michael Klichinsky
Co-Founder & Chief Scientific Officer1.7yrsUS$1.60m1.16%
$ 411.7k
Richard Morris
CFO, Chief Compliance Officer1.7yrsUS$1.66m0%
$ 0
Saar Gill
Co-Founder & Chairman of Scientific Advisory Boardno dataVeri yokVeri yok
Eric Siegel
General Counsel & Corporate Secretary1.4yrsVeri yokVeri yok
Terry Shields
Senior Vice President of Human Resources1.4yrsVeri yokVeri yok
Tom Wilton
Chief Business Officer4.8yrsVeri yokVeri yok
Eugene Kennedy
Chief Medical Officerless than a yearVeri yokVeri yok
Kenneth Locke
Senior Vice President of Technical Operationsless than a yearVeri yokVeri yok

1.5yrs

Ortalama Görev Süresi

52.5yo

Ortalama Yaş

Deneyimli Yönetim: CARM 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.5 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Steven Kelly
President1.7yrsUS$3.50mVeri yok
Saar Gill
Co-Founder & Chairman of Scientific Advisory Boardno dataVeri yokVeri yok
Sanford Zweifach
Independent Chairman of the Board1.7yrsUS$271.55k0.00099%
$ 351.3
Hyam Levitsky
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Carl June
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Nina Bhardwaj
Member of Scientific Advisory Board4.3yrsVeri yokVeri yok
Briggs W. Morrison
Independent Director1.7yrsUS$220.20k0.029%
$ 10.3k
Marella Thorell
Directorless than a yearVeri yokVeri yok
John Hohneker
Independent Directorless than a yearVeri yok0%
$ 0
Lisa Coussens
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Prasad Adusumilli
Member of Scientific Advisory Board4.3yrsVeri yokVeri yok
Lin Guey
Member of Scientific Advisory Board1.8yrsVeri yokVeri yok

1.7yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CARM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.7 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.